Carazolol
From Wikipedia, the free encyclopedia
 |
|
|
Carazolol
|
|
| Systematic (IUPAC) name | |
| 1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol | |
| Identifiers | |
| CAS number | |
| ATC code | C |
| PubChem | |
| Chemical data | |
| Formula | C18H22N2O3 |
| Mol. mass | 298.38 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Carazolol is a high affinity antagonist/partial inverse agonist (also referred to as a beta blocker) of the β-adrenergic receptor.[1]
[edit] References
- ^ Innis RB, Corrēa FM, Synder SH (1979). "Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes". Life Sci. 24 (24): 2255–64. PMID 41147.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
